Carla A Jaeger

Title: Innovations in Cancer Therapy: The Contributions of Carla A. Jaeger

Introduction

Carla A. Jaeger is a prominent inventor based in Seattle, WA, known for her groundbreaking work in the field of cancer therapy. With a focus on engineered proteins, her research aims to enhance T cell manufacturing for therapeutic applications. Her innovative approach has the potential to significantly improve cancer treatment outcomes.

Latest Patents

Carla A. Jaeger holds a patent for "Engineered trimeric CD70 proteins and uses thereof." This patent describes engineered trimeric CD70 proteins designed for use in ex vivo T cell manufacturing. The use of these proteins during the manufacturing process results in expanded T cell populations with enhanced properties. These properties include earlier proliferation in culture, selective expansion of naïve and memory T cell subsets, longer persistence in vivo following administration, and improved therapeutic effects. The proteins also provide anti-cancer and anti-viral effects, making them valuable in therapeutic applications.

Career Highlights

Carla A. Jaeger is affiliated with the Fred Hutchinson Cancer Center, where she contributes to cutting-edge research in cancer immunotherapy. Her work is instrumental in advancing the understanding and application of engineered proteins in clinical settings.

Collaborations

Carla collaborates with esteemed colleagues, including Colin Correnti and Stanley R. Riddell, to further enhance the impact of her research in the field of immunotherapy.

Conclusion

Carla A. Jaeger's innovative contributions to engineered proteins represent a significant advancement in cancer therapy. Her work not only enhances T cell manufacturing but also holds promise for improved therapeutic outcomes in cancer treatment.